These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 18671148

  • 41. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD.
    Ichinose M, Seyama K, Nishimura M, Fukuchi Y, Nagai A, Mishima M, Kubo K, Beta-2 Agonist Research and Evaluation Committee in COPD (BAREC) Study Group.
    Respir Med; 2010 Feb; 104(2):267-74. PubMed ID: 19875277
    [Abstract] [Full Text] [Related]

  • 42. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

  • 43. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG.
    COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
    [Abstract] [Full Text] [Related]

  • 44. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [Abstract] [Full Text] [Related]

  • 45. Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD.
    Andò F, Ruggeri P, Girbino G, Cazzola M.
    Respir Med; 2008 Jun; 102(6):815-8. PubMed ID: 18343646
    [Abstract] [Full Text] [Related]

  • 46. Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10): 948-55.
    Sampablo I, Carone M, Antoniu SA.
    Expert Opin Pharmacother; 2010 Jun; 11(8):1439-41. PubMed ID: 20446856
    [Abstract] [Full Text] [Related]

  • 47. Effects of replacing oxitropium with tiotropium on pulmonary function in patients with COPD: a randomized study.
    Incorvaia C, Riario-Sforza GG, Pravettoni C, Dugnani N, Paterniti F, Pessina L, Fumagalli M.
    Respir Med; 2007 Mar; 101(3):476-80. PubMed ID: 16919926
    [Abstract] [Full Text] [Related]

  • 48. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
    Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, Bateman E.
    Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
    [Abstract] [Full Text] [Related]

  • 49. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.
    Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP, UPLIFT Study Investigators.
    Am J Respir Crit Care Med; 2009 Nov 15; 180(10):948-55. PubMed ID: 19729663
    [Abstract] [Full Text] [Related]

  • 50. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease.
    Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, Stephenson AL, Stukel TA.
    JAMA; 2014 Sep 17; 312(11):1114-21. PubMed ID: 25226477
    [Abstract] [Full Text] [Related]

  • 51. The role of corticosteroids in chronic obstructive pulmonary disease.
    Calverley PM.
    Semin Respir Crit Care Med; 2005 Apr 17; 26(2):235-45. PubMed ID: 16088440
    [Abstract] [Full Text] [Related]

  • 52. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.
    Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW.
    Arch Intern Med; 2010 May 24; 170(10):880-7. PubMed ID: 20498416
    [Abstract] [Full Text] [Related]

  • 53. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD.
    Verhamme KM, Afonso AS, van Noord C, Haag MD, Koudstaal PJ, Brusselle GG, Sturkenboom MC.
    Pulm Pharmacol Ther; 2012 Feb 24; 25(1):19-26. PubMed ID: 22051450
    [Abstract] [Full Text] [Related]

  • 54. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.
    Singh S, Loke YK, Enright P, Furberg CD.
    Thorax; 2013 Jan 24; 68(1):114-6. PubMed ID: 22764216
    [Abstract] [Full Text] [Related]

  • 55. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
    Gagnon YM, Levy AR, Spencer MD, Hurley JS, Frost FJ, Mapel DW, Briggs AH.
    Respir Med; 2005 Dec 24; 99(12):1534-45. PubMed ID: 16291076
    [Abstract] [Full Text] [Related]

  • 56. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes.
    Yohannes AM, Willgoss TG, Vestbo J.
    Respir Care; 2011 Apr 24; 56(4):477-87. PubMed ID: 21255503
    [Abstract] [Full Text] [Related]

  • 57. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.
    Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB.
    Thorax; 2008 Apr 24; 63(4):301-5. PubMed ID: 17951276
    [Abstract] [Full Text] [Related]

  • 58. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.
    Somand H, Remington TL.
    Ann Pharmacother; 2005 Sep 24; 39(9):1467-75. PubMed ID: 16030078
    [Abstract] [Full Text] [Related]

  • 59. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)].
    Szmidt M.
    Pneumonol Alergol Pol; 2012 Sep 24; 80(3):255-62. PubMed ID: 22562275
    [Abstract] [Full Text] [Related]

  • 60. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.
    Respir Med; 2008 Jul 24; 102(7):1033-44. PubMed ID: 18479895
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.